Baicalein and Baicalin Inhibit SARS-CoV-2 RNA-Dependent-RNA Polymerase

Coronavirus Disease 2019 (COVID-19) is a deadly emerging infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is easily transmitted through the air and has a relatively long incubation time, COVID-19 has rapidly developed into a global pandemi...

Full description

Saved in:
Bibliographic Details
Published in:Microorganisms (Basel) Vol. 9; no. 5; p. 893
Main Authors: Zandi, Keivan, Musall, Katie, Oo, Adrian, Cao, Dongdong, Liang, Bo, Hassandarvish, Pouya, Lan, Shuiyun, Slack, Ryan L., Kirby, Karen A., Bassit, Leda, Amblard, Franck, Kim, Baek, AbuBakar, Sazaly, Sarafianos, Stefan G., Schinazi, Raymond F.
Format: Journal Article
Language:English
Published: Switzerland MDPI AG 22.04.2021
MDPI
Subjects:
air
Antiviral activity
Antiviral agents
antiviral properties
baicalein
Baicalin
Cell culture
coronavirus
Coronaviruses
COVID-19
COVID-19 infection
Disease transmission
DNA-directed RNA polymerase
Experiments
Flavonoids
Infections
Infectious diseases
pandemic
Pandemics
pathogens
Proteins
Respiratory diseases
RNA polymerase
RNA-directed RNA polymerase
SARS-CoV-2
Severe acute respiratory syndrome coronavirus 2
Software
therapeutics
Viral diseases
Viruses
St Louis Missouri
United States > US
Virginia
COVID-19
SARS-CoV-2
baicalin
antiviral agents
RdRp
nsp12
coronavirus
baicalein
flavonoid
ISSN:2076-2607, 2076-2607
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Coronavirus Disease 2019 (COVID-19) is a deadly emerging infectious disease caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Because SARS-CoV-2 is easily transmitted through the air and has a relatively long incubation time, COVID-19 has rapidly developed into a global pandemic. As there are no antiviral agents for the prevention and treatment of this severe pathogen except for remdesivir, development of antiviral therapies to treat infected individuals remains highly urgent. Here, we showed that baicalein and baicalin exhibited significant antiviral activity against SARS-CoV-2, the causative agent of COVID-19 through in vitro studies. Our data through cell-based and biochemical studies showed that both compounds act as SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) inhibitors directly and inhibit the activity of the SARS-CoV-2 RdRp, but baicalein was more potent. We also showed specific binding of baicalein to the SARS-CoV-2 RdRp, making it a potential candidate for further studies towards therapeutic development for COVID-19 as a selective non-nucleoside polymerase inhibitor.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2076-2607
2076-2607
DOI:10.3390/microorganisms9050893